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A B S T R A C T
Lentigo maligna melanoma (LMM) is a slowly growing tumor of elderly white population. It typically develops on
chronically sun-exposed skin of the head and neck area which indicates that the cumulative exposure to the UV radiation
has crucial role in the development of LMM. Precursor lesion is lentigo maligna (LM) which commonly presents as an ir-
regular brownish pigmented macular lesion persisting for years. Women are affected more often as men by LMM, with
the average age of over 60 years. The age of onset has dropped over the past years and this tumour is nowadays also diag-
nosed in 40-year-old individuals. However, the incidence rate increases with age and peaks in the seventh and eighth de-
cades of life. The prognosis for invasive lentigo maligna melanoma does not differ from that for other histogenetic types
of melanoma after controlling for tumour thickness. The diagnosis and treatment of LMM remain challenging. In this
presentation, we review the epidemiology, clinical presentation, histopathology, and treatment of LMM.
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Cutaneous melanoma is one of the most aggressive
tumors in dermatology1. The incidence has increased
dramatically in all parts of the world over the past 30
years and shows little sign of leveling off2. The incidence
in Croatia is not exceptional. In the past 40 years in
Croatia the incidence of melanoma is also in rise for more
than 300%3. Women and men are almost equally af-
fected. In the last decades, melanoma often occur in rela-
tively younger people, between the age of 25 and 40,
rarely in the childhood. In 2006. i 2007.there were
60,000–62,000 new cases of inavisive tumor and aprox.
48,000 in situ melanoma. However, survival in patients
with melanoma in Western European countries has in-
creased markedly in recent years, due to timely recogni-
tion of the disease, as melanoma is curable by means of
surgical excision if diagnosed in early stages of the di-
sease4. Unfortunately, in Croatia the mortality remains
higher even though the incidence is lower than those in
some Western European countries
Melanoma is classified into 4 main subtypes; superfi-
cial spreading (70%), nodular (10–15%), and acral len-
tiginous melanoma (5%) and lentigo malignant mela-
noma (5-15 %).1 Lentigo maligna (LM) is a subtype of
melanoma in-situ. Most authors refer to this lesion as
LM when it is confined to the epidermis, and as lentigo
malignant melanoma (LMM) when it invades the dermis.
Epidemiological data
Many authors consider lentigo maligna to be a pre-
invasive lesion induced by long-term cumulative ultravi-
olet injury. It is supported by the fact that its incidence is
the highest in Hawaii island, and the lowest in Scandina-
vian region; the region that has lower ultraviolet index.
The annual incidence of LM in Australia was estimated
at 1.3: 100.0007.
We represent data3 from Croatian Referral Center for
Malignant melanoma. From 2002–2008 there were 974
patients with melanoma and for 590 patients we knew
the histology subtype. 35 patients had Lentigo maligna
melanoma which is 5.9 %. The percentage correlates
with Western European countries data. Women slightly
predominated; 20 women versus 15 men. Generally, pa-
tients with lentigo maligna are older than 40 years, with
a mean age of 65 years. The peak incidence occurs in the
seventh to eighth decades of life.
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Clinical presentation
Lentigo maligna usually develops on chronically sun-
-exposed skin of the head and neck, with a predilection
for the cheek1. In men, it is more often on the left side of
the cheek (drivers side) while as in the women it is on the
right side (passenger’s side)8. A plausible explanation for
this phenomenon is that, according to the Australian
road traffic accident database, most Australian drivers
are men, and most front seat passengers are women.
Lentigo maligna presents as a slowly enlarging tan-
-to-brown macule with ill-de?ned borders that expands
centrifugally with variable shades of tan, brown, dark
brown or black. The lesion often contains net-like black
pigmentation. If darker papule or nodule arises or if the
skin markings are destroyed, then lentigo maligna mela-
noma is developing. Lentigo maligna is usually presented
10 do 15 years before progression to lentigo maligna mel-
anoma, but several cases observed rapid progression.
The exact percentage of LM cases
that progress to LMM is unknown. Weinstock and So-
ber estimated an approximate 5% lifetime risk of LMM
in patients diagnosed with LM at age 45. However, in two
series of 85
LM excisions, more than 50% contained occult inva-
sive foci of melanoma, and, in a more recent report of 92
consecutive cases, 16% of LM lesions undergoing staged
excisions harbored unexpected foci of invasion9.
Clinically, the main differential diagnosis includes so-
lar lentigo, pigmented actinic keratosis, and seborrheic
keratosis1.
Diagnosis
The most ideal method is excisional biopsy but as
these lesions are sometimes quite large, the punch biop-
sies or incisionals biopsy in full thickness are optional, al-
though it is very easy to miss the invasive foci10. The one
should clinical search for more pigmented or slightly ele-
vated parts of the lesion. It is recommended that biopsy
is read by patologist experienced in pigmented lesion.
ALthough the best diagnostical method is patohisto-
logical analysis, dermatocsopy can aslo be helpfull11.
Histopathology
Lentigo malignais prototype of horizontal phase of
melanoma. When atypical melanocytes begin to grow
down into the dermis, the vertical growth fase has begin,
representing lentigo maligna melanoma. The hallmark
of lentigo maligana is the proliferation of the atypical
melanocytes in the epidermal basal layer. there is an in-
creased number of clear cells, many of which are large, ir-
regular or polygonal or which may have atypical nuclei.
Sometimes nests of these cells may be seen, often located
in a free space below the epidermis but not invading the
dermis. In addition the epidermis is usually thinned.
Some dermatopathologist take the presence of nests as a
criterion for the diagnosis of melanoma in situ. In the
dermis there is always marked solar elastosis. As it is al-
ways deifficult to determine borders of a lentigo maligna,
monocolonal antibodies such as HMB45 and S100 B may
help to indentify the melanocytes but cannot asses their
biological role1.
Treatment
Treatment for the lentiogo maligna in siti is exci-
sional biopsy and reexcision after the patohistological
confirmation12. It offers the lowest recurrence rates.
However, not every lesion is suitable for the complete ex-
cision and not every patient is candidate for the surgical
procedure, there are several non.surgical modalities as
an option. The most widely used is chriotherapy of the le-
sion. There is no standard procedure how it should be
done, but some authors recommend a double freeze (30
to 60 s) – thaw cycle. Cryotherapy may be given with or
without local anesthetic. Healing of cryosurgical wounds
usually takes longer than excisional wounds do, and the
cosmetic results may vary 13.The post-treatment area is
often dyspigmented, and it may be difficult to know if the
lesion was cured or if residual disease remains and may
necessitate a biopsy to exclude the recurrence.
The radiation therapy showed very low recurrence
rate and cosmetically results were promising. Recently
there are several reports about beneficial usage od 5 %
imiquimod, but this should be considered as experimen-
tal before larger studies are made14.
In the case of lentigo malignant melanoma it is as for
every other subtype of melanoma. After the patohisto-
logical analysis confirmed the diagnosis, the reexcision is
done and if the lesion is thicker than 1 milimetar, senti-
nel biopsy should be performed. Follow up is done accord-
ing of the stage of the disease.
Conclusion
Lentigo maligna should be the goal of the treatment.
The differential diagnosis is wide and expect the knowl-
edge, the experience in pigment lesion is also important.
In the head and neck region, the one should be especially
alert as there is a large number of lesion that are induced
by the ultraviolet rays and it is sometimes difficult to dis-
tinguish from each other on the sun-demaged skin.
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S A @ E T A K
Lentigo maligni melanom (LMM) je sporo rastu}i tumor starije dobi, koji poga|a uglavnom bijelu rasu. LMM se
gotovo uvijek razvija na predjelima ko`e kroni~no izlo`enim suncu, odnosno u podru~ju glave i vrata, ponajprije na nosu
i obrazima, {to navodi na zaklju~ak da je kumulativan u~inak UV zra~enja presudan u nastajanju ovog oblika mela-
noma. Prekursorska promjena – lentigo maligna (LM) o~ituje se kao nejednoliko sme|a mrlja razli~ita oblika, koja traje
godinama. LMM se ~e{}e dijagnosticira u `ena nego u mu{karaca, u prosje~noj dobi od preko 60 godina. Iako je dobna
granica u kojoj se dijagnosticira LMM zna~ajno je ni`a posljednjih godina, te se danas ovaj oblik melanoma mo`e vidjeti
i u dobi od 40 godina, jo{ uvijek kod LMM incidencija raste s dobi i naj~e{}e se dijagnosticira u ljudi u sedmom ili osmom
desetlje}u `ivota. Kao i kod drugih oblika melanoma, debljina tumora predstavlja najva`niji prognosti~ki ~imbenik.
Dijagnostika i lije~enje LMM ~esto predstavljaju klini~ki izazov. U ovom izlaganju bit }e rije~ o epidemiologiji, klini~koj
slici, histologiji i lije~enju LMM.
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